Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-03-30Clinical Trial Update: Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC) [Phase 2]
Phase 2 trial of selinexor (KPT-330) in metastatic triple-negative breast cancer has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2017-03-22Clinical Trial Update: Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients [Phase 2]
A Phase 2 neoadjuvant trial in triple-negative breast cancer compares regimens of SAR240550 with weekly paclitaxel versus paclitaxel alone.
-
CLINICAL_TRIALS trial_result · 2017-03-20Clinical Trial Update: Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer [Phase 2]
A Phase 2 trial evaluating brostallicin with cisplatin in metastatic triple-negative breast cancer has completed, with results posted in 201…
-
CLINICAL_TRIALS trial_result · 2017-01-20Clinical Trial Update: Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer [Phase 2]
Phase 2 study evaluating the safety and efficacy of Onartuzumab and/or Bevacizumab in combination with Paclitaxel for metastatic triple-nega…
-
CLINICAL_TRIALS trial_result · 2017-01-19Clinical Trial Update: Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer [Phase 2]
This clinical trial update covers a Phase 2 study of erlotinib in combination with chemotherapy for triple-negative breast cancer. The curre…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-11-22Clinical Trial Update: Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer [Phase 3]
Phase 3 neoadjuvant trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) versus TC (docetaxel and cyclophosphamide) in triple-nega…
-
CLINICAL_TRIALS trial_result · 2016-10-28Clinical Trial Update: Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer [Phase 2]
A Phase 2 neoadjuvant trial of platinum-based chemoradiation for locally advanced triple-negative breast cancer was terminated, with results…
-
CLINICAL_TRIALS trial_result · 2016-10-11Clinical Trial Update: Phase II Pilot Study Assessing Efficacy of a Cisplatin - Métronomic Cyclophosphamide Treatment in Patients With Stade IV Triple Negative Breast Cancer Secondary Resistant to Anthracyclines and Taxanes [Phase 2]
Phase II pilot study evaluating cisplatin with metronomic cyclophosphamide in metastatic, stage IV triple-negative breast cancer resistant t…
-
CLINICAL_TRIALS trial_result · 2016-09-22Clinical Trial Update: Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer [Phase 1, Phase 2]
This update reports on a Phase 1/2 trial evaluating weekly paclitaxel, carboplatin, and bevacizumab as first-line therapy for triple-negativ…
-
CLINICAL_TRIALS trial_result · 2016-09-08Clinical Trial Update: A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers [Phase 1]
Phase 1 safety study of MM-121 in combination with cetuximab and irinotecan in patients with advanced cancers, including colorectal cancer a…
-
CLINICAL_TRIALS trial_result · 2016-08-31Clinical Trial Update: A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer [Phase 2]
A randomized Phase 2 neoadjuvant study comparing weekly paclitaxel with or without the SMAC mimetic LCL161 in triple-negative breast cancer …
-
CLINICAL_TRIALS trial_result · 2016-08-19Clinical Trial Update: Effect of Chemotherapy and Radiation Prior to Surgery for Triple Negative Breast Cancer [Phase 2]
Phase 2 trial evaluating chemotherapy and radiation before surgery for triple-negative breast cancer was terminated; results were posted in …
-
CLINICAL_TRIALS trial_result · 2016-07-07Clinical Trial Update: Cabozantinib for Metastatic Triple Negative BrCa [Phase 2]
A Phase 2 study of cabozantinib in metastatic triple-negative breast cancer has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2016-05-27Clinical Trial Update: A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer [Phase 2]
Phase 2 trial update of bevacizumab with gemcitabine and carboplatin in participants with triple-negative metastatic breast cancer; results …
-
CLINICAL_TRIALS trial_result · 2016-05-25Clinical Trial Update: Phase II ABT-888 With Cyclophosphamide [Phase 2]
Phase II trial evaluating veliparib (ABT-888) in combination with cyclophosphamide across ovarian and related gynecologic cancers; results w…
-
CLINICAL_TRIALS trial_result · 2016-03-21Clinical Trial Update: Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer [Phase 2]
A Phase 2 trial evaluating tivantinib for recurrent or metastatic breast cancer has completed with results posted in 2016.
-
CLINICAL_TRIALS trial_result · 2016-03-17Clinical Trial Update: A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis [Phase 2]
This clinical trial update reports the completion of a Phase 2 study evaluating INIPARIB in combination with chemotherapy for triple-negativ…
-
CLINICAL_TRIALS trial_result · 2016-03-17Clinical Trial Update: Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer [Phase 2]
Phase 2 trial evaluating azacitidine in combination with entinostat in advanced breast cancer has completed and posted results.
-
CLINICAL_TRIALS trial_result · 2016-03-17Clinical Trial Update: A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer [Phase 2]
A Phase 2 trial evaluating standard chemotherapy plus BSI-201 (iniparib) as neoadjuvant therapy for triple-negative breast cancer has comple…
-
CLINICAL_TRIALS trial_result · 2016-03-17Clinical Trial Update: Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer [Phase 2]
Phase 2 trial of bevacizumab plus paclitaxel and capecitabine in triple-negative metastatic breast cancer has been terminated.
-
CLINICAL_TRIALS trial_result · 2016-03-15Clinical Trial Update: Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery [Phase 1]
Phase 1 trial evaluating weekly cilengitide in combination with paclitaxel in adults with advanced, unresectable solid tumors, including bre…
-
CLINICAL_TRIALS trial_result · 2016-03-14Clinical Trial Update: A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer [Phase 2]
Phase 2 trial evaluating preoperative MM-121 with Paclitaxel in HER2-negative breast cancer completed; results were posted in 2016.
-
CLINICAL_TRIALS trial_result · 2016-02-15Clinical Trial Update: Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer [Phase 2, Phase 3]
This update reports on a Phase 2/Phase 3 trial evaluating the addition of carboplatin to neoadjuvant therapy for patients with triple-negati…
-
CLINICAL_TRIALS trial_result · 2015-11-30Clinical Trial Update: Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers [Phase 1]
Phase 1 study evaluating the safety and tolerability of combining everolimus with eribulin in patients with triple-negative breast cancer.
-
CLINICAL_TRIALS trial_result · 2015-11-26Clinical Trial Update: Huaier Granule in Treating Women With Triple Negative Breast Cancer [Phase 4]
Phase 4 clinical trial update evaluating Huaier Granule in women with triple-negative breast cancer. The trial status is listed as UNKNOWN.